US Patent

US8354430 — Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine

Method of Use · Assigned to Bioprojet SC · Expires 2026-02-06 · 0y expired

Vulnerability score 65/100 Moderate — design-around opportunities exist

What this patent protects

A method is provided for treating sleep apnea and other conditions by administering an effective amount of a specific crystalline form of pitolisant hydrochloride to a patient.

USPTO Abstract

A method is provided for the treatment of sleep apnea and other conditions wherein an effective amount of crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride of formula (I): optionally comprising water up to 6%, and having an X-ray diffractogram that comprises characteristic peaks (2θ) at 11.2°, 19.9°, 20.7° and 34.1°±0.2° is administered to a patient in need thereof.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1101 — pitolisant-hydrochloride
U-1101 — pitolisant-hydrochloride

Patent Metadata

Patent number
US8354430
Jurisdiction
US
Classification
Method of Use
Expires
2026-02-06
Drug substance claim
No
Drug product claim
No
Assignee
Bioprojet SC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.